Modulation of the mineralocorticoid receptor as add-on treatment in depression: A randomized, double-blind, placebo-controlled proof-of-concept study

Journal of Psychiatric Research

Volumn 44, Issue 6, 2010, Pages 339-346

  Otte, Christian ^a   Hinkelmann, Kim ^a   Moritz, Steffen ^a   Yassouridis, Alexander ^b   Jahn, Holger ^a   Wiedemann, Klaus ^a   Kellner, Michael ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antidepressants; Cortisol; Depression; HPA axis; Mineralocorticoid receptor; Stress

Indexed keywords

ESCITALOPRAM; FLUDROCORTISONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PLACEBO; SPIRONOLACTONE;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; AGITATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; XEROSTOMIA;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; INPATIENTS; MALE; MIDDLE AGED; OUTPATIENTS; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950939794     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2009.10.006     Document Type: Article

References (64)

1. Arana G.W., Santos A.B., Laraia M.T., McLeod-Bryant S., Beale M.D., Rames L.J., et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. American Journal of Psychiatry 1995, 152:265-267.
2. Bachmann C.G., Linthorst A.C.E., Holsboer F., Reul J.M.H.M. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 2003, 28:1056.
3. Barden N., Reul J.M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?. Trends in Neurosciences 1995, 18:6-11.
4. Belanoff J.K., Rothschild A.J., Cassidy F., DeBattista C., Baulieu E.E., Schold C., et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry 2002, 52:386-392.
5. Binneman B., Feltner D., Kolluri S., Shi Y., Qiu R., Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. American Journal of Psychiatry 2008, 165:617-620.
6. Bitran D., Shiekh M., Dowd J.A., Dugan M.M., Renda P. Corticosterone is permissive to the anxiolytic effect that results from the blockade of hippocampal mineralocorticoid receptors. Pharmacology Biochemistry and Behaviour 1998, 60:879-887.
7. Blockmans D., Persoons P., Van Houdenhove B., Lejeune M., Bobbaers H. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. The American Journal of Medicine 2003, 114:736.
8. Brady L.S., Whitfield H.J., Fox R.J., Gold P.W., Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. Journal of Clinical Investigation 1991, 87:831-837.
9. Brinks V, vanderMark M, deKloet E, Oitzl MS. Differential MR/GR activation in mice results in emotional states beneficial or impairing for cognition. Neural Plasticity, 2007 [Article ID 90163].
10. Buckley T.M., Mullen B.C., Schatzberg A.F. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology 2007, 32:859-864.
11. Bundesgesundheitsberichterstattung, 2008. http://www.gbe-bund.de/.
12. de Kloet E.R., Joels M., Holsboer F. Stress and the brain: from adaptation to disease. Nature Reviews Neuroscience 2005, 6:463-475.
13. DeBattista C., Belanoff J., Glass S., Khan A., Horne R.L., Blasey C., et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biological Psychiatry 2006, 60:1343-1349.
14. DeBattista C., Posener J.A., Kalehzan B.M., Schatzberg A.F. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. American Journal of Psychiatry 2000, 157:1334-1337.
15. deKloet E., deRijk R., Meijer O. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression?. Nature Clinical Practice Endocrinology and Metabolism 2007, 3:168-179.
16. Drevets W.C., Frank E., Price J.C., Kupfer D.J., Holt D., Greer P.J., et al. PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 1999, 46:1375-1387.
17. Gallagher P, Malik N, Newham J, Young AH, Ferrier IN, Mackin P. Antiglucocorticoid treatments for mood disorders. Cochrane Database of Systematic Reviews, 2008, CD005168.
18. Gelenberg A., Thase M., Meyer R., Goodwin F., Katz M., Kraemer H., et al. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. Journal of Clinical Psychiatry 2008, 69:1513-1528.
19. Gesing A., Bilang-Bleuel A., Droste S.K., Linthorst A.C., Holsboer F., Reul J.M. Psychological stress increases hippocampal mineralocorticoid receptor levels: involvement of corticotropin-releasing hormone. Journal of Neurosciences 2001, 21:4822-4829.
20. Grossmann C., Scholz T., Rochel M., Bumke-Vogt C., Oelkers W., Pfeiffer A.F., et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. European Journal of Endocrinology 2004, 151:397-406.
21. Hlavacova N., Jezova D. Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Hormones and Behaviour 2008, 54:90-97.
22. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. Journal of Psychiatric Research 1999, 33:181-214.
23. Holsboer F., Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. European Journal of Pharmacology 2008, 583:350-357.
24. Insel T.R., Charney D.S. Research on major depression: strategies and priorities. JAMA 2003, 289:3167-3168.
25. Jahn H., Schick M., Kiefer F., Kellner M., Yassouridis A., Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of General Psychiatry 2004, 61:1235-1244.
26. Joels M. Functional actions of corticosteroids in the hippocampus. European Journal of Pharmacology 2008, 583:312-321.
27. Joels M., Karst H., DeRijk R., de Kloet E.R. The coming out of the brain mineralocorticoid receptor. Trends in Neurosciences 2008, 31:1-7.
28. Juruena M., Cleare A., Papadopoulos A., Poon L., Lightman S., Pariante C. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology 2006, 189:225.
29. Juruena M.F., Gama C.S., Berk M., Belmonte-de-Abreu P.S. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. Journal of Psychopharmacology 2008.
30. Juruena M.F., Pariante C.M., Papadopoulos A.S., Poon L., Lightman S., Cleare A.J. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. The British Journal of Psychiatry 2009, 194:342-349.
31. Keller M. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 2003, 289:3152-3160.
32. Kellner M., Wiedemann K. Mineralocorticoid receptors in brain, in health and disease: possibilities for new pharmacotherapy. European Journal of Pharmacology 2008, 583:372-378.
33. Korte S.M., de Boer S.F., de Kloet E.R., Bohus B. Anxiolytic-like effects of selective mineralocorticoid and glucocorticoid antagonists on fear-enhanced behavior in the elevated plus-maze. Psychoneuroendocrinology 1995, 20:385-394.
34. Kuningas M., de Rijk R.H., Westendorp R.G.J., Jolles J., Eline Slagboom P., van Heemst D. Mental performance in old age dependent on cortisol and genetic variance in the mineralocorticoid and glucocorticoid receptors. Neuropsychopharmacology 2006, 32:1295.
35. Lai M., Horsburgh K., Bae S.-E., Carter R.N., Stenvers D.J., Fowler J.H., et al. Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. European Journal of Neuroscience 2007, 25:1832-1842.
36. Lopez J., Little K., Lopez-Figueroa A., Lopez-Figueroa M., Watson S. Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biological Psychiatry 2003, 53:173S.
37. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biological Psychiatry 1998, 43:547-573. A.E. Bennett Research Award.
38. Montgomery S., Baldwin D., Blier P., Fineberg N., Kasper S., Lader M., et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. International Clinical Psychopharmacology 2007, 22:323-329.
39. Murck H., Held K., Ziegenbein M., Kunzel H., Koch K., Steiger A. The Renin-Angiotensin-Aldosterone system in patients with depression compared to controls - a sleep-endocrine study. BMC Psychiatry 2003, 3:15.
40. Nelson J.C., Davis J.M. DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry 1997, 154:1497-1503.
41. Nemeroff C.B., Owens M.J. Treatment of mood disorders. Nature Neuroscience 2002, 5(Suppl.):1068-1070.
42. NIMH. Breaking ground, breaking through: the strategic plan for mood disorders research of the National Institute of Mental Health. 2003. http://www.nimh.nih.gov/strategic/mooddisorders.pdf.
43. O'Brien P.M., Craven D., Selby C., Symonds E.M. Treatment of premenstrual syndrome by spironolactone. British Journal of Obstetrics and Gynaecology 1979, 86:142-147.
44. Otte C., Jahn H., Yassouridis A., Arlt J., Stober N., Maass P., et al. The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sciences 2003, 73:1835-1845.
45. Otte C., Moritz S., Yassouridis A., Koop M., Madrischewski A.M., Wiedemann K., et al. Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 2007, 32:232.
46. Otte C., Yassouridis A., Jahn H., Maass P., Stober N., Wiedemann K., et al. Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. Journal of Gerontology A: Biological Sciences and Medical Sciences 2003, 58:B900-B905.
47. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends in Neurosciences 2008, 31:464.
48. Posener J.A., DeBattista C., Williams G.H., Chmura Kraemer H., Kalehzan B.M., Schatzberg A.F. 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Archives of General Psychiatry 2000, 57:755-760.
49. Reul J.M., Stec I., Soder M., Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 1993, 133:312-320.
50. Rowe P.C., Calkins H., DeBusk K., McKenzie R., Anand R., Sharma G., et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001, 285:52-59.
51. Rozeboom A.M., Akil H., Seasholtz A.F. Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proceedings of the National Academy of Sciences 2007, 104:4688-4693.
52. Schatzberg A.F., Lindley S. Glucocorticoid antagonists in neuropsychiatric disorders. European Journal of Pharmacology 2008, 583:358-364.
53. Seckl J.R., Fink G. Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology 1992, 55:621-626.
54. Smythe J.W., Murphy D., Timothy C., Costall B. Hippocampal mineralocorticoid, but not glucocorticoid, receptors modulate anxiety-like behavior in rats. Pharmacology Biochemistry and Behaviour 1997, 56:507-513.
55. Wang M., Hammarback S., Lindhe B.A., Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstetricia et Gynecologica Scandinavica 1995, 74:803-808.
56. Wang S.S., Kamphuis W., Huitinga I., Zhou J.N., Swaab D.F. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Molecular Psychiatry 2008, 13:786.
57. Wernze H. Überraschende Wirkungen von Spironolacton auf Essverhalten und Befindensparameter bei Bulimie. Psychopharmakotherapie 2000, 7:33-39.
58. WHO, 2007. http://www.who.int/whosis/whostat2007_10highlights.pdf.
59. Wolkowitz O.M., Reus V.I., Chan T., Manfredi F., Raum W., Johnson R., et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biological Psychiatry 1999, 45:1070-1074.
60. Yau J.L., Hibberd C., Noble J., Seckl J.R. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Research and Molecular Brain Research 2002, 106:117-123.
61. Yau J.L., Noble J., Hibberd C., Seckl J.R. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neuroscience Letters 2001, 306:161-164.
62. Yau J.L., Olsson T., Morris R.G., Meaney M.J., Seckl J.R. Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience 1995, 66:571-581.
63. Young E.A., Lopez J.F., Murphy-Weinberg V., Watson S.J., Akil H. Mineralocorticoid receptor function in major depression. Archives of General Psychiatry 2003, 60:24-28.
64. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. Journal of Psychiatric Research 2000, 34:171-181.